Swiss drugmaker Novartis on Sunday said it agreed to acquire US biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare muscle disorders. Avidity stockholders will receive...

Swiss drugmaker Novartis on Sunday said it agreed to acquire US biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare muscle disorders. Avidity stockholders will receive...

No posts found

No posts found